Table 1.
Patient selection and clinical data.
| Pt | CA125 (t0) | CA125 (t1) | Ascites mL (t0) | Ascites mL (t1) | PIV (t0) | PIV (t1) | Histology |
|---|---|---|---|---|---|---|---|
| 1 | 20 597 | 938.5 | 200 | < 100 mL | 8 |
HGSOC FIGO IV |
|
| 2 | 4697.1 | 139.1 | 4900 | 0 | 8 | 4 |
HGSOC FIGO IIIC |
| 3 | 1022.4 | 443.2 | 1800 | 300 | 8 | 2 |
HGSOC FIGO IIIC |
| 4 | 9797 | 25.6 | 7000 | < 100 mL | 10 | 4 |
HGSOC FIGO IIIC |
| 5 | 302.4 | 11.7 | 2000 | 0 | 10 | 4 |
HGSOC FIGO IV |
| 6 | 1329.5 | 30.4 | < 100 mL | 0 | 8 | 2 |
HGSOC FIGO IIIC |
| 7 | 5639 | 107.9 | 4000 | < 100 mL | 8 | 6 |
HGSOC FIGO IIIC |
| 8 | 2875.2 | 132.8 | 3700 | < 100 mL | 8 | 6 |
HGSOC FIGO IIIC |
HGSOC, high‐grade serous ovarian cancer; PIV, predictive index value (Fagotti score); PLR, platelet‐to‐lymphocyte ratio; t0, diagnosis; t1, post‐neoadjuvant chemotherapy (post‐NACT).